WINDLAS Q1 FY27 Share Price & Earnings Call Analysis

Financials of WINDLAS

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of WINDLAS

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +141145153162171175187195203210222233238
Expenses +124128134142149154164170177184194209213
Operating Profit16171920222123252627292425
OPM %12%12%12%13%13%12%12%13%13%13%13%10%11%
Other Income +2333445455454
Interest0000001111111
Depreciation4333466787888
Profit before tax15161820231820202123242020
Tax %24%26%23%24%25%26%23%23%22%24%25%25%21%
Net Profit +11121415171316161618181516
EPS in Rs5.385.806.757.268.176.457.497.457.778.438.457.127.58

Financials of WINDLAS

Profit & Loss

Annual income statement trend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +352307329428466513631760904
Expenses +313270295373414453553666799
Operating Profit3938345552607894105
OPM %11%12%10%13%11%12%12%12%12%
Other Income +4542-19710131818
Interest653111145
Depreciation17119131212132831
Profit before tax207625224657778087
Tax %44%16%34%28%16%25%25%24%24%
Net Profit +116416163843586166
EPS in Rs20.0499.5525.2824.6917.4820.0427.9829.1031.49
Dividend Payout %0%0%0%0%20%20%20%20%20%

Financials of WINDLAS

Balance Sheet

Capital structure and asset base

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital66661110101011
Reserves119187203193384392440495570
Borrowings +573229327543335
Other Liabilities +107731006590122173222291
Total Liabilities290298338296491529626760907
Fixed Assets +8664709691109179223217
CWIP535008156556
Investments231221162365107173223268
Other Assets +128107152177327298268308366
Total Assets290298338296491529626760907

Financials of WINDLAS

Cash Flows

Operating, investing and financing cash movement

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +3519251196110968105
Cash from Investing Activity +-11-7-14-20-155-14-92-74-92
Cash from Financing Activity +-26-6-51130-44-151-13
Net Cash Flow-265-8-1532-50
Free Cash Flow1010106-6-9711637
CFO/OP102%81%113%33%34%117%163%95%115%

Financials of WINDLAS

Ratios

Working capital efficiency and return ratios

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days697371688783798092
Inventory Days543685557184576340
Days Payable130110143537698121129156
Cash Conversion Cycle-7-1137081691514-24
Working Capital Days-30-1224085713217123
ROCE %15%12%19%15%14%18%17%16%

Others in Pharmaceuticals & Biotechnology this season

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Ind-Swift Laboratories Ltd (Q1 FY27)

    Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…

  • HIKAL (Q1 FY27)

    400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…

Compare:vs SUNPHARMAvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd